↓ Skip to main content

Dove Medical Press

Article Metrics

Riluzole 5 mg/mL oral suspension: for optimized drug delivery in amyotrophic lateral sclerosis

Overview of attention for article published in Drug Design, Development and Therapy, December 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#7 of 1,899)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news
37 news outlets
twitter
1 tweeter
patent
1 patent

Citations

dimensions_citation
19 Dimensions

Readers on

mendeley
81 Mendeley
Title
Riluzole 5 mg/mL oral suspension: for optimized drug delivery in amyotrophic lateral sclerosis
Published in
Drug Design, Development and Therapy, December 2016
DOI 10.2147/dddt.s123776
Pubmed ID
Authors

Ann Margaret Dyer, Alan Smith

Abstract

The aim of the present work is to extensively evaluate the pharmaceutical attributes of currently available riluzole presentations. The article describes the limitations and risks associated with the administration of crushed tablets, including the potential for inaccurate dosing and reduced rate of absorption when riluzole is administered with high-fat foods, and the advantages that a recently approved innovative oral liquid form of riluzole confers on amyotrophic lateral sclerosis (ALS) patients. The article further evaluates the patented and innovative controlled flocculation technology used in the pseudoplastic suspension formulation to reduce the oral anesthesia seen with crushed tablets, resulting in optimized drug delivery for riluzole. Riluzole is the only drug licensed for treating ALS, which is the most common form of motor neurone disease and a highly devastating neurodegenerative condition. The licensed indication is to extend life or the time to mechanical ventilation. Until recently, riluzole was only available as an oral tablet dosage form in the UK; however, an innovative oral liquid form, Teglutik(®) 5 mg/mL oral suspension, is now available. An oral liquid formulation provides an important therapeutic option for patients with ALS, >80% of who may become unable to swallow solid oral dosage forms due to disease-related dysphagia. Prior to the launch of riluzole oral suspension, the only way for many patients to continue to take riluzole as their disease progressed was through crushed tablets. A novel suspension formulation enables more accurate dosing and consistent ongoing administration of riluzole. There are clear and important advantages such as enhanced patient compliance compared with crushed tablets administered with food or via an enteral feeding tube and the potential for an improved therapeutic outcome and enhanced quality of life for ALS patients.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 81 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 81 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 16 20%
Student > Bachelor 12 15%
Student > Ph. D. Student 8 10%
Student > Postgraduate 6 7%
Researcher 6 7%
Other 8 10%
Unknown 25 31%
Readers by discipline Count As %
Medicine and Dentistry 18 22%
Pharmacology, Toxicology and Pharmaceutical Science 9 11%
Nursing and Health Professions 8 10%
Agricultural and Biological Sciences 7 9%
Neuroscience 4 5%
Other 9 11%
Unknown 26 32%

Attention Score in Context

This research output has an Altmetric Attention Score of 289. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 June 2019.
All research outputs
#78,803
of 20,168,546 outputs
Outputs from Drug Design, Development and Therapy
#7
of 1,899 outputs
Outputs of similar age
#2,721
of 411,574 outputs
Outputs of similar age from Drug Design, Development and Therapy
#2
of 39 outputs
Altmetric has tracked 20,168,546 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,899 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.5. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 411,574 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 39 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.